Dr David Propper

Senior Lecturer; Consultant Medical Oncologist
Group Leader
Email
Research Focus

My focus is on detailed translational trials in pancreatic cancer, with a focus on targeting the tumour microenvironment. Our aim is to define what perturbations occur in tumours of patients receiving trial drugs.

Key Publications

Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. Nat Commun (2020) 24;11(1):4841. PMID: 32973176

Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. Br J Cancer (2020) 122, 1760-1768. PMID: 32350413

Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma. Gut (2019) 68(6):1052-1064. PMID: 30121627

The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAMindependent manner. Nat Commun (2018) 9(1):3279. PMID: 30115931

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncol (2018) 19(4):562-578. PMID: 29611518

Major Funding
  • CRUK
  • Stand Up To Cancer/Lustgarten Foundation
  • MRC
  • Barts Charity
Themes/Keywords
Targeting Tumour Cells Clinical Trials Pancreatic Centre for Tumour Microenvironment
Research

Detailed translational trials in pancreatic cancer, with a focus on targeting the tumour microenvironment.

Our aim is to define what perturbations occur in tumours of patients receiving trial drugs. We have developed sophisticated assays defining drug effects in human tumours and laboratory models. These enable examination at transcriptional, proteomic, immune and metabolic levels.

Current projects include:

Clinical trials and laboratory studies focussed on epigenetic targeting, immune therapies and stromal reprogramming, including cytokine gene therapy.

Major Funding
  • CRUK
  • Stand Up To Cancer/Lustgarten Foundation
  • MRC
  • Barts Charity